Skip to main content
SpringerLink
Log in

Cryotherapy for Management of Prostate Cancer

  • Chapter
  • First Online:
Interventional Urology

Abstract

The aim of focal therapy for prostate cancer is targeted treatment of the clinically significant cancer foci to preserve the genitourinary function. In recent years, advances in training and safety measures have increased the clinical adoption of prostate cryotherapy as an organ conservation minimally invasive cancer surgery. This modality has been increasingly used in both primary and salvage settings, and for both whole and partial gland templates.

In this chapter, the authors reviewed the literature comprehensively and covered different aspects of prostate cancer cryotherapy. The pathophysiology of cryotherapy and the rationale for the effectiveness of cryosurgery on cancer cells have been addressed.

In another section, the authors focused on the details of proper case selection, surgical technique, outcomes, and complications. Notably, several technical challenges, tips and tricks, and oncological and functional outcomes in different scenarios have been discussed. Different follow-up protocols after surgery for detection of recurrence and management of recurrence after cryotherapy are presented.

With evolving role of multiparametric MRI as a noninvasive modality for detection of clinically significant prostate cancer foci, the incorporation of modern imaging modalities in patient selection, for decision-making in ablative therapy as well as designing and surveillance of patients after treatment to detect post-ablation recurrence, has been extensively assessed.

Finally, novel concepts and new areas of investigations in prostate cryotherapy, such as interaction with the tumor microenvironment, resistant tumor stem cells, mutations in tumor cell lines, and the use of adjuvant cryosensitizing agents, are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Gage AA. History of cryosurgery. Semin Surg Oncol. 1998;14(2):99–109.

    Article  CAS  PubMed  Google Scholar 

  2. Gage AA, Baust JG. Cryosurgery for tumors. J Am Coll Surg. 2007;205(2):342–56.

    Article  PubMed  Google Scholar 

  3. Baust JG, Gage AA. Progress toward optimization of cryosurgery. Technol Cancer Res Treat. 2004;3(2):95–101.

    Article  CAS  PubMed  Google Scholar 

  4. Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int. 2012;109:1648–54.

    Article  PubMed  Google Scholar 

  5. Kongnyuy M, Halpern DM, Kosinski KE, Katz AE. Cryosurgery, an alternative treatment option for organ-confined prostate cancer: current beliefs and practice patterns of urologists. Int Urol Nephrol. 2017;49:43–8.

    Article  PubMed  Google Scholar 

  6. Theodorescu D. Cancer cryotherapy: evolution and biology. Rev Urol. 2004;6(Suppl 4):S9–S19.

    PubMed  PubMed Central  Google Scholar 

  7. Young JL, Kolla SB, Pick DL, Sountoulides P, Kaufmann OG, Ortiz-Vanderdys CG, et al. In vitro, ex vivo and in vivo isotherms for renal cryotherapy. J Urol. 2010;183(2):752–8.

    Article  PubMed  Google Scholar 

  8. Shah TT, Arbel U, Foss S, Zachman A, Rodney S, Ahmed HU, Arya M. Modeling cryotherapy ice ball dimensions and isotherms in a novel gel-based model to determine optimal cryo-needle configurations and settings for potential use in clinical practice. Urology. 2016;91:234–40.

    Article  PubMed  Google Scholar 

  9. Hoffmann NE, Bischof JC. The cryobiology of cryosurgical injury. Urology. 2002;60(2 Suppl 1):40–9.

    Article  PubMed  Google Scholar 

  10. Gage AA, Baust JM, Baust JG. Experimental cryosurgery investigations in vivo. Cryobiology. 2009;59(3):229–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Benzon B, Glavaris SA, Simons BW, Hughes RM, Ghabili K, Mullane P, et al. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(1):126–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Udagawa M, Kudo-Saito C, Hasegawa G, Yano K, Yamamoto A, Yaguchi M, et al. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin Cancer Res. 2006;12(24):7465–75.

    Article  CAS  PubMed  Google Scholar 

  13. Cohen JK, Miller RJ Jr, Ahmed S, Lotz MJ, Baust J. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology. 2008;71(3):515–8.

    Article  PubMed  Google Scholar 

  14. Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, Katz AE. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180(2):554–8.

    Article  PubMed  Google Scholar 

  15. Pitman M, Shapiro EY, Hruby GW, Truesdale MD, Cheetham PJ, Saad S, Katz AE. Comparison of biochemical failure definitions for predicting local cancer recurrence following cryoablation of the prostate. Prostate. 2012;72(16):1802–8.

    Article  CAS  PubMed  Google Scholar 

  16. Levy DA, Ross AE, ElShafei A, Krishnan N, Hatem A, Jones JS. Definition of biochemical success following primary whole gland prostate cryoablation. J Urol. 2014;192(5):1380–4.

    Article  CAS  PubMed  Google Scholar 

  17. Levy DA, Pisters LL, Jones JS. Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol. 2009;182(3):931–7.

    Article  CAS  PubMed  Google Scholar 

  18. Babaian RJ, Donnelly B, Bahn D, Baust JG, Dineen M, Ellis D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008;180(5):1993–2004.

    Article  PubMed  Google Scholar 

  19. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al.; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37.

    Google Scholar 

  20. Grossgold E, Given R, Ruckle H, Jones JS. Does neoadjuvant androgen deprivation therapy before primary whole gland cryoablation of the prostate affect the outcome? Urology. 2014;83(2):379–84.

    Article  PubMed  Google Scholar 

  21. Tay KJ, Polascik TJ, Elshafei A, Cher ML, Given RW, Mouraviev V, et al. Primary cryotherapy for high-grade clinically localized prostate cancer: oncologic and functional outcomes from the COLD Registry. J Endourol. 2016;30(1):43–8.

    Article  PubMed  Google Scholar 

  22. Chen CH, Pu YS. Adjuvant androgen-deprivation therapy following prostate total cryoablation in high-risk localized prostate cancer patients – open-labeled randomized clinical trial. Cryobiology. 2018;82:88–92.

    Article  CAS  PubMed  Google Scholar 

  23. Tsivian M, Polascik TJ. Cryotherapy of the prostate. In: Smith AD, Badlani GH, Preminger GM, Kavoussi LR, editors. Smith’s textbook of endourology. 3rd ed. Oxford: Wiley-Blackwell; 2012. p. 1406–15.

    Chapter  Google Scholar 

  24. Mouraviev V, Evans B, Polascik TJ. Salvage prostate cryoablation after primary interstitial brachytherapy failure: a feasible approach. Prostate Cancer Prostatic Dis. 2006;9(1):99–101.

    Article  CAS  PubMed  Google Scholar 

  25. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, et al. Anatomical vc cancer. J Urol. 2015;194(6):1624–30.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Ng CK, Moussa M, Downey DB, Chin JL. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. J Urol. 2007;178(4 Pt 1):1253–7.

    Article  PubMed  Google Scholar 

  27. Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer. 2006;107(2):275–80.

    Article  CAS  PubMed  Google Scholar 

  28. Spiess PE, Levy DA, Mouraviev V, Pisters LL, Jones JS. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model. BJU Int. 2013;112(4):E256–61.

    Article  CAS  PubMed  Google Scholar 

  29. Hubosky SG, Fabrizio MD, Schellhammer PF, Barone BB, Tepera CM, Given RW. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. J Endourol. 2007;21(12):1521–31.

    Article  PubMed  Google Scholar 

  30. DiBlasio CJ, Derweesh IH, Malcolm JB, Maddox MM, Aleman MA, Wake RW. Contemporary analysis of erectile, voiding, and oncologic outcomes following primary targeted cryoablation of the prostate for clinically localized prostate cancer. Int Braz J Urol. 2008;34(4):443–50.

    Article  PubMed  Google Scholar 

  31. Prepelica KL, Okeke Z, Murphy A, Katz AE. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer. 2005;103(8):1625–30.

    Article  PubMed  Google Scholar 

  32. Cresswell J, Asterling S, Chaudhary M, Sheikh N, Greene D. Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease. BJU Int. 2006;97(5):969–74.

    Article  PubMed  Google Scholar 

  33. Donnelly BJ, Saliken JC, Brasher PM, Ernst SD, Rewcastle JC, Lau H, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer. 2010;116(2):323–30.

    Article  CAS  PubMed  Google Scholar 

  34. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002;60(2 Suppl 1):3–11.

    Article  PubMed  Google Scholar 

  35. Oishi M, Gill IS, Ashrafi AN, Lin-Brande M, Nassiri N, Shin T, et al. Primary whole-gland cryoablation for prostate cancer: biochemical failure and clinical recurrence at 5.6 years of follow-up. Eur Urol. 2019;75(2):208–14.

    Article  PubMed  Google Scholar 

  36. Liu YY, Chiang PH, Chuang YC, Lee WC, Cheng YT, Wang HJ. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation. Ann Surg Oncol. 2015;22(5):1612–7.

    Article  PubMed  Google Scholar 

  37. Elshafei A, Kovac E, Dhar N, Levy D, Polascik T, Mouraviev V, et al. A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate. Prostate. 2015;75(13):1447–53.

    Article  CAS  PubMed  Google Scholar 

  38. Gao L, Yang L, Qian S, Tang Z, Qin F, Wei Q, Han P, Yuan J. Cryosurgery would be an effective option for clinically localized prostate cancer: a meta-analysis and systematic review. Sci Rep. 2016;6:27490.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Siddiqui KM, Billia M, Al-Zahrani A, Williams A, Goodman C, Arifin A, et al. Long-term oncologic outcomes of salvage cryoablation for radio-recurrent prostate cancer. J Urol. 2016;196(4):1105–11.

    Article  PubMed  Google Scholar 

  40. Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int. 2007;100(4):760–4.

    Article  PubMed  Google Scholar 

  41. Li R, Ruckle HC, Schlaifer AE, El-Shafei A, Yu C, Jones JS. The effect of androgen deprivation therapy before salvage whole-gland cryoablation after primary radiation failure in prostate cancer treatment. Urology. 2015;85(5):1137–42.

    Article  PubMed  Google Scholar 

  42. Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180(2):559–63.

    Article  PubMed  Google Scholar 

  43. Wenske S, Quarrier S, Katz AE. Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre. Eur Urol. 2013;64(1):1–7.

    Article  PubMed  Google Scholar 

  44. Tetreault-Laflamme A, Crook J. Options for salvage of radiation failures for prostate cancer. Semin Radiat Oncol. 2017;27(1):67–78.

    Article  PubMed  Google Scholar 

  45. Zdrojowy R, Dembowski J, Małkiewicz B, Tupikowski K, Krajewski W. Salvage local therapy for radiation-recurrent prostate cancer – where are we? Cent Eur J Urol. 2016;69(3):264–70.

    Google Scholar 

  46. Golbari NM, Katz AE. Salvage therapy options for local prostate cancer recurrence after primary radiotherapy: a literature review. Curr Urol Rep. 2017;18(8):63.

    Article  PubMed  Google Scholar 

  47. McClure TD, Margolis DJ, Hu JC. Partial gland ablation in the management of prostate cancer: a review. Curr Opin Urol. 2017;27(2):156–60.

    Article  PubMed  Google Scholar 

  48. Rukstalis DB, Goldknopf JL, Crowley EM, Garcia FU. Prostate cryoablation: a scientific rationale for future modifications. Urology. 2002;60(2 Suppl 1):19–25.

    Article  PubMed  Google Scholar 

  49. Valerio M, Donaldson I, Emberton M, Ehdaie B, Hadaschik BA, Marks LS, et al. Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review. Eur Urol. 2015;68(1):8–19.

    Article  PubMed  Google Scholar 

  50. Nguyen CT, Jones JS. Focal therapy in the management of localized prostate cancer. BJU Int. 2011;107(9):1362–8.

    Article  PubMed  Google Scholar 

  51. Durand M, Barret E, Galiano M, Rozet F, Sanchez-Salas R, Ahallal Y, et al. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU Int. 2014;113(1):56–64.

    Article  PubMed  Google Scholar 

  52. Kongnyuy M, Lipsky MJ, Islam S, Robins DJ, Hager S, Halpern DM, et al. Predictors of biochemical recurrence after primary focal cryosurgery (hemiablation) for localized prostate cancer: a multi-institutional analytic comparison of Phoenix and Stuttgart criteria. Urol Oncol. 2017;35(8):530.e15–9.

    Article  Google Scholar 

  53. Patel P, Mathew MS, Trilisky I, Oto A. Multiparametric MR imaging of the prostate after treatment of prostate cancer. Radiographics. 2018;38(2):437–49.

    Article  PubMed  Google Scholar 

  54. De Visschere PJ, De Meerleer GO, Fütterer JJ, Villeirs GM. Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol. 2010;194(6):1427–33.

    Article  PubMed  Google Scholar 

  55. Kim CK, Park BK, Park W, Kim SS. Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging. 2010;35(2):246–52.

    Article  PubMed  Google Scholar 

  56. Kongnyuy M, Halpern DM, Liu CC, Kosinski KE, Habibian DJ, Corcoran AT, Katz AE. 3-T multiparametric MRI characteristics of prostate cancer patients suspicious for biochemical recurrence after primary focal cryosurgery (hemiablation). Int Urol Nephrol. 2017;49(11):1947–54.

    Article  CAS  PubMed  Google Scholar 

  57. Muller BG, van den Bos W, Brausi M, Fütterer JJ, Ghai S, Pinto PA, et al. Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. World J Urol. 2015;33(10):1503–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Lambert EH, Bolte K, Masson P, Katz AE. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology. 2007;69(6):1117–20.

    Article  PubMed  Google Scholar 

  59. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. The “male lumpectomy”: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol. 2008;26(5):500–5.

    Article  PubMed  Google Scholar 

  60. Dhar N, Cher ML, Scionti SM, Lugnani F, Jones JS. Focal/partial gland prostate cryoablation: results of 795 patients from multiple centers tracked with the COLD registry (abstract). J Urol. 2009;181(4 Suppl):715.

    Google Scholar 

  61. Faure Walker NA, Norris JM, Shah TT, Yap T, Cathcart P, Moore CM, Ahmed HU, Emberton M, Minhas S. A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: a systematic review. Urol Oncol. 2018;36(2):67–76.

    Article  PubMed  Google Scholar 

  62. Mendez MH, Passoni NM, Pow-Sang J, Jones JS, Polascik TJ. Comparison of outcomes between preoperatively potent men treated with focal versus whole gland cryotherapy in a matched population. J Endourol. 2015;29(10):1193–8.

    Article  PubMed  Google Scholar 

  63. Garcia-Barreras S, Sanchez-Salas R, Sivaraman A, Barret E, Secin F, Nunes-Silva I, et al. Comparative analysis of partial gland ablation and radical prostatectomy to treat low and intermediate risk prostate cancer: oncologic and functional outcomes. J Urol. 2018;199(1):140–6.

    Article  PubMed  Google Scholar 

  64. Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007;69(1):62–9.

    Article  PubMed  Google Scholar 

  65. de Castro Abreu AL, Bahn D, Leslie S, Shoji S, Silverman P, Desai MM, Gill IS, et al. Salvage focal and salvage total cryoablation for locally recurrent prostate cancer after primary radiation therapy. BJU Int. 2013;112(3):298–307.

    Article  PubMed  Google Scholar 

  66. Eisenberg ML, Shinohara K. Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. Urology. 2008;72(6):1315–8.

    Article  PubMed  Google Scholar 

  67. Li YH, Elshafei A, Agarwal G, Ruckle H, Powsang J, Jones JS. Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry. Prostate. 2015;75(1):1–7.

    Article  PubMed  Google Scholar 

  68. Duijzentkunst DA, Peters M, van der Voort van Zyp JR, Moerland MA, van Vulpen M. Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. World J Urol. 2016;34(11):1521–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Marigliano C, Donati OF, Vargas HA, Akin O, Goldman DA, Eastham JA, et al. MRI findings of radiation-induced changes in the urethra and periurethral tissues after treatment for prostate cancer. Eur J Radiol. 2013;82(12):e775–81.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M 3rd, Jung AJ, Carroll PR, Coakley FV. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012;82(5):e787–93.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Sala E, Eberhardt SC, Akin O, Moskowitz CS, Onyebuchi CN, Kuroiwa K, et al. Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology. 2006;238(1):176–83.

    Article  PubMed  Google Scholar 

  72. Wu LM, Xu JR, Gu HY, Hua J, Zhu J, Chen J, et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol (R Coll Radiol). 2013;25(4):252–64.

    Article  CAS  Google Scholar 

  73. Berglund RK, Jones JS. Cryotherapy for prostate cancer. In: Rastinehad AR, Siegel DN, editors. Interventional urology. Cham: Springer International; 2016. p. 165–71.

    Chapter  Google Scholar 

  74. Aminsharifi A, Polascik TJ, Schulman A, Tay KJ, Jibara G, Sze C, et al. Predictors of rectourethral fistula formation after primary whole-gland cryoablation for prostate cancer: results from the Cryo On-Line Database registry. J Endourol. 2018;32(9):791–6.

    Article  PubMed  Google Scholar 

  75. Elliott SP, Meng MV, Elkin EP, McAninch JW, Duchane J, Carroll PR, CaPSURE Investigators. Incidence of urethral stricture after primary treatment for prostate cancer: data from CaPSURE. J Urol. 2007;178(2):529–34.

    Article  PubMed  Google Scholar 

  76. Browne BM, Vanni AJ. Management of urethral stricture and bladder neck contracture following primary and salvage treatment of prostate cancer. Curr Urol Rep. 2017;18(10):76.

    Article  PubMed  Google Scholar 

  77. Robinson JW, Donnelly BJ, Siever JE, Saliken JC, Ernst SD, Rewcastle JC, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer. 2009;115(20):4695–704.

    Article  PubMed  Google Scholar 

  78. Kimura M, Mouraviev V, Tsivian M, Moreira DM, Mayes JM, Polascik TJ. Analysis of urinary function using validated instruments and uroflowmetry after primary and salvage prostate cryoablation. Urology. 2010;76(5):1258–65.

    Article  PubMed  Google Scholar 

  79. Mateu L, Peri L, Franco A, Roldán F, Musquera M, Ribal MJ. Functional outcomes after prostatic cryosurgery. Actas Urol Esp. 2018;42(5):338–43.

    Article  CAS  PubMed  Google Scholar 

  80. Peters M, Moman MR, van der Poel HG, Vergunst H, de Jong IJ, Vijverberg PL, et al. Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review. World J Urol. 2013;31(2):403–9.

    Article  PubMed  Google Scholar 

  81. Pisters LL. Cryotherapy for prostate cancer: ready for prime time? Curr Opin Urol. 2010;20(3):218–22.

    Article  PubMed  Google Scholar 

  82. Leibovich BC, Blute ML, Bostwick DG, Wilson TM, Pisansky TM, Davis BJ, et al. Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology. 2000;56(5):726–9.

    Article  CAS  PubMed  Google Scholar 

  83. Favazza CP, Gorny KR, King DM, Rossman PJ, Felmlee JP, Woodrum DA, Mynderse LA. An investigation of the effects from a urethral warming system on temperature distributions during cryoablation treatment of the prostate: a phantom study. Cryobiology. 2014;69(1):128–33.

    Article  CAS  PubMed  Google Scholar 

  84. Woodrum DA, Kawashima A, Gorny KR, Mynderse LA. Prostate cancer: state of the art imaging and focal treatment. Clin Radiol. 2017;72(8):665–79.

    Article  CAS  PubMed  Google Scholar 

  85. Tay KJ, Scheltema MJ, Ahmed HU, Barret E, Coleman JA, Dominguez-Escrig J, et al. Patient selection for prostate focal therapy in the era of active surveillance: an international Delphi consensus project. Prostate Cancer Prostatic Dis. 2017;20(3):294–9.

    Article  CAS  PubMed  Google Scholar 

  86. Shah TT, Peters M, Eldred-Evans D, Miah S, Yap T, Faure-Walker NA, et al. Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry. Eur Urol. 2019 Jul;76(1):98–105.

    Article  PubMed  Google Scholar 

  87. Ganzer R, Arthanareeswaran VK, Ahmed HU, Cestari A, Rischmann P, Salomon G, et al. Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement. Prostate Cancer Prostatic Dis. 2018;21(2):175–86.

    Article  CAS  PubMed  Google Scholar 

  88. Baust JM, Rabin Y, Polascik TJ, Santucci KL, Snyder KK, Van Buskirk RG, Baust JG. Defeating cancers' adaptive defensive strategies using thermal therapies: examining cancer's therapeutic resistance, ablative, and computational modeling strategies as a means for improving therapeutic outcome. Technol Cancer Res Treat. 2018;17:1533033818762207.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Baust JM, Klossner DP, Robilotto A, Vanbuskirk RG, Gage AA, Mouraviev V, et al. Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis. BJU Int. 2012;109(6):949–58.

    Article  CAS  PubMed  Google Scholar 

  90. Baust JG, Bischof JC, Jiang-Hughes S, Polascik TJ, Rukstalis DB, Gage AA, Baust JM. Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue. Prostate Cancer Prostatic Dis. 2015;18(2):87–95.

    Article  CAS  PubMed  Google Scholar 

  91. Yuan F, Zhou W, Zhang J, Zhang Z, Zou C, Huang L, et al. Anticancer drugs are synergistic with freezing in induction of apoptosis in HCC cells. Cryobiology. 2008;57(1):60–5.

    Article  CAS  PubMed  Google Scholar 

  92. Shenoi MM, Iltis I, Choi J, Koonce NA, Metzger GJ, Griffin RJ, Bischof JC. Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy. Mol Pharm. 2013;10(5):1683–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

Dr. Polascik has a consultant agreement with Endocare for physician training.

Author information

Authors and Affiliations

  1. Department of Urology, Pennsylvania State University, Hershey Medical Center, Hershey, PA, USA

    Alireza Aminsharifi

  2. Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran

    Alireza Aminsharifi

  3. Duke Prostate and Genitourinary Cancer Center, Departments of Surgery and Urology, Duke Medical Center, Durham, NC, USA

    Thomas J. Polascik

Authors
  1. Alireza Aminsharifi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas J. Polascik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alireza Aminsharifi .

Editor information

Editors and Affiliations

  1. Urology and Radiology, Lenox Hill Hospital, New York, NY, USA

    Ardeshir R. Rastinehad

  2. Vascular & Interventional Radiology, North Shore Long Island Jewish Health System, New Hyde Park, NY, USA

    David N. Siegel

  3. National Cancer Institute & Clinica, Bethesda, MD, USA

    Bradford J. Wood

  4. Lefrak Center for Robotic Surgery, Weill Cornell Medicine, New York, NY, USA

    Timothy McClure

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Aminsharifi, A., Polascik, T.J. (2021). Cryotherapy for Management of Prostate Cancer. In: Rastinehad, A.R., Siegel, D.N., Wood, B.J., McClure, T. (eds) Interventional Urology . Springer, Cham. https://doi.org/10.1007/978-3-030-73565-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-73565-4_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-73564-7

  • Online ISBN: 978-3-030-73565-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation